All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
On 21st March 2017, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) gave Positive Scientific Advice for a trial of iomab-B (a radioimmuno conjugate of a murine monoclonal antibody that targets CD45 [an antigen widely expressed on leukemia cells]) in patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). The EMA previously awarded orphan designation to iomab-B in October 2016.
Currently in the United States (U.S), iomab-b is being explored in a pivotal phase 3 SIERRA study (NCT02665065), which is aiming to evaluate the efficacy of iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic Hematopoietic Cell Transplant (HCT) in 150 patients (55 years and above) with R/R AML. The primary and secondary endpoints of this study were durable complete remission at 6 months and overall survival at 1 year, respectively.
On the phase 3 SIERRA trial, the EMA CHMP remarked that the trial design, primary endpoint, and planned statistical analysis are satisfactory and can serve as the basis for submission of a Marketing Authorization Application. Additionally, the EMA noted that it does not anticipate the need for further standalone preclinical toxicology or safety studies. However, supporting data and information that are already being collected as part of the U.S. pivotal phase 3 SIERRA trial were requested by the EMA.
Iomab-B, once approved, is intended to be an induction and conditioning agent prior to HCT in R/R AML patients.
References